Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Omega Diagnostics provides update ahead of AGM

Published 15/09/2021, 09:04
Updated 15/09/2021, 09:07
© Reuters.

By Samuel Indyk

Investing.com – Omega Diagnostics (LON:ODX) shares were trading lower on Wednesday morning after the company provided an update ahead of its Annual General Meeting (AGM).

Simon Douglas, Omega’s Non-executive Chairman, said the diagnostics company is confident they are well positioned for exciting growth, and this remains the case moving towards the second half of the year.

Covid-19

On testing for Covid-19, Omega said they remain confident in delivering significant value from the space. The company reported “positive” dialogue with third parties which are advancing. Omega said they are optimistic these will conclude successfully and have a positive impact on performance in the second half of the year.

The company confirmed they are still waiting for their European Notified Body to complete the review of their submission for CE marking for self-test use of their Visitect antigen test. Once this is approved, the company expects this to provide the catalyst for further sales opportunities.

Disappointment may have come following the update on regulatory approvals for the AbC-19 rapid test.

Omega announced that advancement towards further regulatory approvals and commercial progress is continuing but there is no further news to update shareholders on this progress. Omega reassured that the prospects for the test have not changed, and they still believe there is significant opportunity for this Covid-19 antibody test.

Non-Covid

The company said its Health and Nutrition Division is continuing to show early signs of recovery towards pre-pandemic revenue levels.

Omega also said they remain confident about the long-term prospects for the roll out of the Visitect CD4 test for the effective management of HIV. The company said they remain confident in the market potential for the product reaching 4-6 million tests a year within the next three to five years, representing an opportunity to generally £12-£18 million in annualised revenues.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

At 09:01BST, shares in Omega were trading lower by 5.4% at 52.1 pence per share. The AGM begins at 11:00BST.  

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.